Disclosures for "Identifying Novel Pathways to Tackle the Proinflammatory Potential of Mesenchymal Stem Cells from Multiple Sclerosis Patients"
-
Dr. Tanasescu has received personal compensation for serving as an employee of Merck. Dr. Tanasescu has received personal compensation for serving as an employee of Novartis. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Tanasescu has received research support from UK MRC grant MR/T024402/1.
-
Ms. Frakich has nothing to disclose.
-
Dr. Gumireddy has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Thevathas has nothing to disclose.
-
Prof. Jones has nothing to disclose.
-
Dr. Gran has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead. Dr. Gran has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche UK. Dr. Gran has received publishing royalties from a publication relating to health care.
-
Dr. Onion has nothing to disclose.
-
Dr. Wickramasinghe has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Kossenkov has nothing to disclose.
-
Dr. Spendlove has nothing to disclose.
-
Dr. Colombo has nothing to disclose.
-
Prof. SHOWE has nothing to disclose.
-
Dr. Constantinescu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD SErono. Dr. Constantinescu has received publishing royalties from a publication relating to health care.